🔗 Share this article

Government ministers and leading parliamentarians have issued warnings that the United Kingdom's series of deals with the US administration are "fundamentally unstable." This stems from revelations that a recently announced deal on pharmaceutical tariffs, which promises zero tariffs in exchange for the NHS paying more, lacks any detailed agreement beyond vague headline terms outlined by government press releases.

A Deal Without Detail

The US-UK pharmaceuticals agreement, hailed as a "landmark" achievement, is still an "agreement in principle" without formal ratification. Critics have noted that the press releases from the UK and US governments describe the deal in sharply different terms. The British version emphasizes securing "duty-free access" as a unique achievement, while the American announcement dwells on the agreement for the NHS to pay 25% more for new medications.

"There is a serious risk that the UK government has agreed to terms to increase medicine costs in return for nothing more than a pledge from President Trump," commented David Henig, a trade policy analyst. "We know he has form for not keeping promises."

Broader Instability and a Paused Tech Deal

Concerns have been intensified by Washington's move to pause the major technology agreement, which was previously called "a generational step-change" in the bilateral relationship. The US claimed a failure to advance from the UK on lowering trade barriers as the reason for the pause.

In a separate development, concessions agreed to for British farmers as part of an May trade agreement have still not been formally signed off by the US, despite a looming January deadline. "We have been informed that that the US has not yet signed off the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

In confidential discussions, ministers have expressed concerns that the government's deals with Washington are lacking substance. One minister was quoted as stating the series of agreements as "resting on shaky ground," while another framed the situation as the "current reality" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, chair of the health select committee, argued: "What is even more astonishing than the administration's tactics is the UK government's naive belief that his administration is a trustworthy negotiator. The NHS is too precious to be gambled with."

A Mixed Picture of Success and Setback

Government figures have attempted to minimize the risk of the US reneging on the pharmaceuticals deal. One source indicated the US pharmaceutical industry itself had been advocating for the agreement, desiring stability on imports and pricing, making it less abstract than the paused tech deal.

Officials admit that unpredictability is a feature of dealing with the current US leadership. However, they argue that the UK has obtained tangible results for businesses, such as reduced duties on automobiles compared to other nations. "Securing 25% steel tariffs, which is more favorable than the rate for the rest of the world, is a concrete advantage," one official said.

However, delays have arisen in enacting the initial US-UK accord. Promised quotas on beef exports have not materialized, and the commitment to "eliminate duties on UK metals" has not been fulfilled, with tariffs remaining at 25%.

Looking ahead, the two sides have scheduled to restart talks on the suspended digital agreement in January, following what were described as "constructive" meetings between UK and US officials in Washington.